USFDA issues complete response letter for proposed biosimilar Insulin Aspart: Biocon https://ift.tt/Txr4g8l

The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the application.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/WGtg3QI
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.